Research type:
|
NICE Technology Assessment Report (TAR) |
Title (lead author) etc:
|
Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation (Burch) 290 pages, Volume 13, number 58 |
Link to NICE guidance page
|
|
DOI
|
10.3310/hta13580 |
View/print executive summary
View/print abstract
View full text in pdf format (3333 KB)
 This title is available on our CD-ROM of the journal.
 Order a CD-ROM - free of charge worldwide.
Go to our correspondence page to comment on this publication
|
Headline: |
Study found that, despite some concerns, the use of neuraminidase inhibitors in at-risk populations appeared to be a cost-effective approach for the treatment of influenza, and when data were available for adverse events and complication rates, there was little overall difference associated with the use of either zanamivir or oseltamivir when compared individually with placebo |
This report should be referenced as follows: |
Burch J, Paulden M, Conti S, Stock C, Corbett M, Welton N J, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess
2009;13(58).
|
Project ref: |
07/74/01 |
Original project title: |
Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation |
Chief Investigator: |
Centre for Reviews and Dissemination (CRD), University of York
|
Start Date: |
December 2007 |
Date of publication in HTA journal series |
December 2009
|
Cost: |
This project was commissioned by the HTA programme on behalf of the National Institute for Health and Clinical Excellence on a call-off contract basis |
Project Protocol: |
Project protocol not available
|
Printed copies of this title despatched:
|
115 (Figures relate to the previous calendar month) |
URL of this page: |
http://www.hta.ac.uk/1701 |
News feeds